Download full report with analyst certification and important disclosures
Dec 2 2021, 08:30 GMT
Foods
Novozymes and DSM announce acquisitions; Symrise CEO contract extended to 2025
- Sectors : Foods
- Companies : Givaudan | Kerry Group | Symrise | dsm-firmenich
Ratings
Ratings and price correct at time of issue
| Company | Rating | Date | Previous Rating | Date | Closing Price |
|---|---|---|---|---|---|
| dsm-firmenich | OUTPERFORM | 09/10/20 | Neutral | 13/02/20 | 19080c |
| Givaudan | OUTPERFORM | 24/03/20 | Neutral | 21/06/12 | 449000chf |
| Kerry Group | OUTPERFORM | 30/06/09 | N/A | N/A | 10790c |
| Symrise | OUTPERFORM | 24/03/20 | Neutral | 15/01/19 | 12495c |
DAVY VIEW
It has been a busy week for M&A deals in the ingredients sector as Novozymes and DSM have announced acquisitions. Novozymes is to advance its position in human health and functional food through a 60% acquisition in Synergia Life Sciences (Synergia). Synergia produces a clinically-backed portfolio of probiotics for various applications across functional and dietary supplements, which Novozymes intends to integrate into its acquisition-led BioHealth portfolio. DSM is set to move up the vertical integration ladder through its acquisition of plant-based protein feedstock producer Vestkorn Milling (Vestkorn). Vestkorn supplies an array of protein, starches and dietary fibres used in plant-based protein production, which complements DSM’s existing sustainable food offering. Both deals emphasize the ongoing industry focus on building science-backed ingredients portfolios to meet growing functional health demand.
